Drug intelligence / Profile preview

trametinib + nivolumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of trametinib, a MEK inhibitor that blocks enzymes needed for cell growth, and nivolumab, an anti-PD-1 immunotherapy drug that promotes tumor-killing effects of T-cells by blocking immune checkpoints. This combination has been studied primarily in clinical trials for BRAF-mutated melanoma, often as part of triplet therapy with BRAF inhibitors like dabrafenib.

Brand names: OpdivoMekinist
Other names: nivolumab + trametinib

Targets

PDCD1 (Programmed cell death protein 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on trametinib + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trametinib + nivolumab.

Explore the full profile